Pediapharm Appoints Vice-President, Marketing & Sales and Correction from Source-Options Granted

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE
UNITED STATES


Pediapharm Inc. ("Pediapharm" or the "Corporation") (TSX VENTURE:PDP) is pleased
to announce the appointment of Mr. Richard Labelle as Vice-President, Marketing
and Sales. Mr. Labelle was until recently Vice-President and General Manager of
the Consumer Health division at Sanofi Canada.


"This change in our commercial structure had become necessary in order to
maximize our future growth. Richard's addition to our team is excellent news for
Pediapharm. He brings solid leadership, proven track record and a wealth of
experience and expertise in strategic planning and execution" stated Sylvain
Chretien, President and CEO of Pediapharm. Mr. Chretien added: "Richard's
experience with integrations of acquisitions and with pharmaceutical product
launches will be extremely beneficial to the Corporation." 


Mr. Labelle has obtained a bachelor's degree in business administration from
Universite du Quebec a Montreal as well as a MBA from McGill-HEC Montreal. 


Pediapharm also wishes to confirm that, in order to maximize the commercial
structure, Mr. Ashok Bhaseen remains with Pediapharm as Business Unit Director -
Consumer Health. In this key role, Mr. Bhaseen will be, among other
responsibilities, leading the Corporation's efforts in achieving continued
accelerated growth of NYDA, one of the key Pediapharm products. 


The Board has granted 225,000 stock options to Richard Labelle under its
employee stock option plan, subject to regulatory and TSX Venture Exchange
approval. The options were issued with an exercise price of $0.46 per share,
have a term of ten (10) years and have vesting provisions such that they vest
over four (4) years. 


The Corporation also wishes to correct inaccurate information relating to the
number of outstanding options granted under its employee stock option plan
contained in its news release issued on January 23, 2014. The January 23, 2014
news release incorrectly indicated that 3,810,000 options had been granted to
directors, officers and employees of the Corporations while in fact 3,585,000
options had been granted. 


After giving effect to the 225,000 options granted to Mr. Labelle described
above, the Corporation now has granted a total of 3,810,000 options.


About Pediapharm 

Pediapharm is the only Canadian specialty pharmaceutical company dedicated to
serving the needs of the pediatric community. Its mission is to bring to the
Canadian market the latest innovative pediatric products with the objective to
improve the health and the well-being of children in Canada. Since its debut in
2008, Pediapharm has entered into numerous commercial agreements with partners
from Canada and other countries around the world. The company's innovative
product portfolio includes NYDA(R); a breakthrough treatment for head lice;
EpiCeram(R) a non-steroid emulsion for eczema; KoolEffect(TM) which reduces the
symptoms of fever; and VapoLyptus(TM) a soothing vapour patch of Eucalyptus and
Camphor. 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Sylvain Chretien, President and Chief Executive Officer
Pediapharm Inc.
514-762-2626 ext. 201
sylvain.chretien@pedia-pharm.com


Roland Boivin, Chief Financial Officer
Pediapharm Inc.
514-762-2626 ext. 202
roland.boivin@pedia-pharm.com

Pediapharm Inc. (TSXV:PDP)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024